Andrea Calcagno
Andrea Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
بريد إلكتروني تم التحقق منه على
عدد مرات الاقتباسات
عدد مرات الاقتباسات
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era
E Cerrato, F D'Ascenzo, G Biondi-Zoccai, A Calcagno, S Frea, ...
European heart journal 34 (19), 1432-1436, 2013
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19
S Sciascia, F Aprà, A Baffa, S Baldovino, D Boaro, R Boero, S Bonora, ...
Clin Exp Rheumatol 38 (3), 529-532, 2020
Cardiovascular disease in HIV patients: from bench to bedside and backwards
E Cerrato, A Calcagno, F D'ascenzo, G Biondi-Zoccai, M Mancone, ...
Open heart 2 (1), 2015
Ultrasensitive assessment of residual HIV viraemia in HAART‐treated patients with persistently undetectable plasma HIV‐RNA: A cross‐sectional evaluation
S Bonora, E Nicastri, A Calcagno, D Gonzalez de Requena, G D'Ettorre, ...
Journal of medical virology 81 (3), 400-405, 2009
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis
F D'Ascenzo, E Cerrato, A Calcagno, W Grossomarra, F Ballocca, ...
Atherosclerosis 240 (1), 197-204, 2015
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system
A Calcagno, G Di Perri, S Bonora
Clinical pharmacokinetics 53 (10), 891-906, 2014
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T> C polymorphism
M Siccardi, A D'Avolio, S Nozza, M Simiele, L Baietto, FR Stefani, D Moss, ...
Pharmacogenetics and genomics 20 (12), 759-765, 2010
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
A D'Avolio, A Ciancio, M Siccardi, A Smedile, L Baietto, M Simiele, ...
Therapeutic drug monitoring 34 (2), 165-170, 2012
Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control
A Calcagno, M Simiele, MC Alberione, M Bracchi, L Marinaro, S Ecclesia, ...
Clinical Infectious Diseases 60 (2), 311-317, 2015
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function
A Calcagno, DG de Requena, M Simiele, A D'Avolio, MC Tettoni, ...
Antimicrobial agents and chemotherapy 57 (4), 1840-1843, 2013
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years
G Guaraldi, A Malagoli, A Calcagno, C Mussi, BM Celesia, F Carli, ...
BMC geriatrics 18 (1), 99, 2018
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
A D'Avolio, C Carcieri, J Cusato, M Simiele, A Calcagno, S Allegra, ...
Journal of Antimicrobial Chemotherapy 69 (11), 3061-3066, 2014
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis
S Gili, W Grosso Marra, F D'Ascenzo, E Lonni, A Calcagno, M Cannillo, ...
European heart journal 37 (48), 3600-3609, 2016
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics
A Calcagno, A Yilmaz, J Cusato, M Simiele, R Bertucci, M Siccardi, ...
Aids 26 (12), 1529-1533, 2012
Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
DG de Requena, A Calcagno, S Bonora, L Ladetto, A D'Avolio, ...
Aids 20 (15), 1977-1979, 2006
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV‐positive patients using dried sample spot devices
A Calcagno, A D'Avolio, M Simiele, J Cusato, R Rostagno, V Libanore, ...
British journal of clinical pharmacology 74 (1), 134-140, 2012
Impact of pre-therapy viral load on virological response to modern first-line HAART
MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, C Gori, L Fabeni, ...
International Medical Press 18 (7), 867-876, 2013
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting
M Siccardi, A D'Avolio, S Rodriguez-Novoa, L Cuenca, M Simiele, ...
Therapeutic drug monitoring 34 (2), 232-235, 2012
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment
A D'Avolio, A Ciancio, M Siccardi, A Smedile, M Simiele, J Cusato, ...
Therapeutic drug monitoring 34 (6), 722-728, 2012
HIV infection and primary prevention of cardiovascular disease: lights and shadows in the HAART era
F Ballocca, S Gili, F D’Ascenzo, WG Marra, M Cannillo, A Calcagno, ...
Progress in cardiovascular diseases 58 (5), 565-576, 2016
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20